Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000862
Abstract: The steady advances in oncology bring a host of therapeutic options for older adults (≤65 years old) with cancer. As these patients experience this proliferation of anticancer therapies, their caregivers too have witnessed their role… read more here.
Keywords: caregiver; advanced cancers; review; cancer ... See more keywords
Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-20-0047
Abstract: The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n=978) and on-treatment (n=171) ctDNA samples across 16 advanced stage tumor types… read more here.
Keywords: treatment; circulating tumor; advanced cancers; patients advanced ... See more keywords
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2526
Abstract: 2526Background: Gemcitabine (gem) with nab-paclitaxel (nab-p) is known to have antitumor activity and a favorable toxicity profile. The addition of bevacizumab (bev) to nab-paclitaxel has also been found to enhance nab-paclitaxel cytotoxicity. Methods: We therefore… read more here.
Keywords: nab paclitaxel; bevacizumab; gemcitabine; study ... See more keywords
A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2548
Abstract: 2548Background: PI3K/mTOR and MAPK pathways are aberrantly activated in many tumours and interact to promote tumour growth and therapeutic resistance. Activity of single pathway inhibition is limit... read more here.
Keywords: study vistusertib; vistusertib combination; selumetinib patients; advanced cancers ... See more keywords
EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm11060487
Abstract: For more than three decades, enhanced permeability and retention (EPR)-effect-based nanomedicines have received considerable attention for tumor-selective treatment of solid tumors. However, treatment of advanced cancers remains a huge challenge in clinical situations because of… read more here.
Keywords: effect enhancers; delivery; epr effect; effect ... See more keywords